Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000030
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred revenue | (272) | (261) |
| Net cash used for operating activities | (14,806) | (23,400) |
| Investing activities: | ||
| Capital expenditures | (52) | (135) |
| Net cash used for investing activities | (52) | (135) |
| Financing activities: | ||
| Proceeds from common stock issued under public equity offering-ATM, net | 4,759 | 21,360 |
| Proceeds from exercise of stock options, net | 1 | — |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s capex?
- Aquestive Therapeutics, Inc. (AQST) reported capex of $52K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s capex changed year-over-year?
- Aquestive Therapeutics, Inc.'s capex decreased by 61.5% year-over-year, from $135K to $52K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s capex has grown at a -11.4% compound annual growth rate (CAGR), from $913K to $562K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Aquestive Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude